The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use. [electronic resource]
Producer: 20150112Description: 421-5 p. digitalISSN:- 1549-490X
- Aniline Compounds -- adverse effects
- Drug Approval
- Drug Resistance, Neoplasm -- genetics
- Europe
- European Union
- Female
- Fusion Proteins, bcr-abl -- antagonists & inhibitors
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Male
- Middle Aged
- Mutation
- Nitriles -- adverse effects
- Protein Kinase Inhibitors -- adverse effects
- Quinolines -- adverse effects
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.